11/21
12:57 pm
jazz
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $207.00 price target on the stock.
Low
Report
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $207.00 price target on the stock.
11/21
12:55 pm
jazz
Rating for JAZZ
Low
Report
Rating for JAZZ
11/21
12:55 pm
jazz
Rating for JAZZ
Low
Report
Rating for JAZZ
11/18
07:32 am
jazz
Rating for JAZZ
Medium
Report
Rating for JAZZ
11/18
07:32 am
jazz
Rating for JAZZ
Medium
Report
Rating for JAZZ
11/7
08:36 am
jazz
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $207.00 price target on the stock.
Medium
Report
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $207.00 price target on the stock.
11/7
08:07 am
jazz
Rating for JAZZ
Medium
Report
Rating for JAZZ
11/7
08:07 am
jazz
Rating for JAZZ
Medium
Report
Rating for JAZZ
10/23
03:08 pm
jazz
Rating for JAZZ
Low
Report
Rating for JAZZ
10/23
03:08 pm
jazz
Rating for JAZZ
Low
Report
Rating for JAZZ
10/4
11:50 am
jazz
Rating for JAZZ
Low
Report
Rating for JAZZ
10/4
11:50 am
jazz
Rating for JAZZ
Low
Report
Rating for JAZZ
9/10
08:01 am
jazz
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $205.00 price target on the stock.
Low
Report
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $205.00 price target on the stock.
9/10
05:35 am
jazz
Rating for JAZZ
Low
Report
Rating for JAZZ
9/10
05:35 am
jazz
Rating for JAZZ
Low
Report
Rating for JAZZ
9/9
12:14 pm
jazz
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $140.00 price target on the stock.
Low
Report
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $140.00 price target on the stock.
9/9
11:42 am
jazz
Rating for JAZZ
Low
Report
Rating for JAZZ